A Randomized, Placebo-Controlled, Double-Blinded Trial of Duloxetine in the Treatment of General Fatigue in Patients With Chronic Fatigue Syndrome

Arnold, Lesley M.; Blom, Thomas J.; Welge, Jeffrey A.; Mariutto, Elizabeth; Heller, Alicia

doi:10.1016/j.psym.2014.12.003

Cited by 15 publications

(8 citation statements)

References 28 publications

(37 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, the findings in this study and others in nondepressed older samples suggest that there may be other biological pathways that explain decrements in age‐related energy capacity that have ramifications for treatment of LLD (Brown et al ; Choi et al ; Coen et al ). Furthermore, these differences in energy capacity that occur as age increases may have implications for treatment; for example, in patients with chronic fatigue syndrome, patients' level of physical fatigue did not improve with antidepressant treatment (Arnold et al ). In identifying the biological pathways associated with fatigability in later life, interventions can be designed to target these mechanisms to improve energy capacity and in turn potentially decrease depressive symptomatology.…”

Section: Discussionmentioning

confidence: 99%

Muscle fatigability and depressive symptoms in later life

Brown

Badreddine

Roose

et al. 2017

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Muscle fatigability and depressive symptoms in later life

Brown

Badreddine

Roose

et al. 2017

Int J Geriat Psychiatry

View full text Add to dashboard Cite

show abstract

“…40 In fact, in older adults with depression the presentation of fatigue is more somatic (“physical fatigue”), 41,42 and these differences may have implications for treatment; patients’ mental fatigue but not physical fatigue improves with antidepressant treatment in patients with chronic fatigue syndrome. 43 What follows are candidate pathways that may result in the manifestation of the depressed frail phenotype and specifically the two characteristics of frailty that in the context of LLD incur increased mortality: slow gait and fatigue (Figure 3). …”

Section: Biological Substrates Of the Depressed Frail Phenotypementioning

confidence: 99%

The Depressed Frail Phenotype: The Clinical Manifestation of Increased Biological Aging

Brown

Rutherford

Yaffe

et al. 2016

The American Journal of Geriatric Psychiatry

100

View full text Add to dashboard Cite

Depression in later life is a severe public health problem, associated with higher rates of mortality, suicide, and dementia. Effectiveness of treatment is limited by the failure to deconstruct the heterogeneity of the illness and because diagnostic criteria, pathophysiological models, and treatment algorithms for depression are primarily based on studies of younger adults even though symptoms of the illness and physiology of the patient change with age. Thus, understanding how aging interacts with depressive illness may elucidate endophenotypes of late life depression with different clinical manifestations and underlying mechanisms that can then be targeted with more personalized approaches to treatment. This paper proposes a model for the critical confluence between depression and frailty, a high-risk morbidity and mortality syndrome of later life. This model hypothesizes that characteristics of frailty in adults with late life depression represent the clinical manifestation of greater biological aging and their presence in the context of a depressive illness exposes elders to deleterious trajectories. Potential common biological substrates that may result in the manifestation of the depressed frail phenotype including mitochondrial functioning, dopaminergic neurotransmission, and inflammatory processes and implications for the assessment and treatment of adults with late life depression are discussed. As society continues to live longer, the preservation of the quality of these added years becomes paramount, and the combined impact of depression and frailty on the preservation of this quality warrants the attention of clinical researchers and physicians.

show abstract

“…В настоящее время в лечении СХУ доказана эффективность когнитивно-поведенческой психотерапии, некоторых антидепрессантов, дозированной физической нагрузки [16][17][18][19][20].…”

Section: Introductionunclassified

Chronic fatigue syndrome in the routine hematology practice

Потапенко

Геннадьевич²,

Ballyuzek

et al. 2020

HERALD of North-Western State Medical University named after I.

View full text Add to dashboard Cite

Purpose. Presentation of clinical signs and laboratory profiles of the patients with chronic fatigue syndrome, and comparison of their symptoms with those of the patients with iron deficiency anemia. Materials and methods. Retrospective analysis of the patients symptoms referred to the hematologist outpatient clinic during the period between January 2016 and December 2018. Results. There were 560 patients(162 males and 398 females) referred for a primary consultation by a hematologist. Median age was 52.5 (1894) years. The unexplained fatigue was reported by 27 (4.8%) patients (1 male and 26 females), median age 41 (2466) years. Diagnosis chronic fatigue syndrome (CFS) was confirmed based on the criteria in 17 (63%) patients. 10 patients (47%) with symptoms partially meeting the criteria were diagnosed idiopathic fatigue syndrome (SIF). Half of the patients connected the onset of the diseases with emotional trauma (family issues etc.). The prevailing complaints (30%) were represented by: prolonged fatigue, mild memory impairment and distraction, arthralgia and insomnia. The most frequent reason to see a hematologist was fatigue and borderline changes in the blood tests. Five patients with CFS and 2 patients with SIF were known to have previously diagnosed iron deficient anemia (IDA). Median level of hemoglobin in the patients with severe fatigue and IDA was 10.7 (8.411.7) g/dl. Median follow up duration was 28 (640) months. In the observed group (n = 23) 17% of the patients (n = 4) showed spontaneous improvement. The rest of the patients had reported no changes. The comparison group (n = 64) included the patients with IDA. Most of them (n = 38) did not report fatigue as their initial symptoms (median level of hemoglobin was 9.35 (5.511.9) g/dl). Twenty six patients reported fatigue; median level of hemoglobin was 8.15 (5.911.7) g/dl. The difference between the hemoglobin levels in two groups was significant (р 0.05). However, there was no correlation between the level of hemoglobin and fatigue in the patients with CFS and SIF. The correlation was found in the patients with CFS and SIF between fatigue and patients perception. Conclusion. The main symptoms accompanying CFS are fatigue and other non-specific symptoms which are often related to patients emotional status. Considering CFS as a differential diagnosis when dealing with fatigue is essential.

show abstract

A Randomized, Placebo-Controlled, Double-Blinded Trial of Duloxetine in the Treatment of General Fatigue in Patients With Chronic Fatigue Syndrome

Cited by 15 publications

References 28 publications

Muscle fatigability and depressive symptoms in later life

Muscle fatigability and depressive symptoms in later life

The Depressed Frail Phenotype: The Clinical Manifestation of Increased Biological Aging

Chronic fatigue syndrome in the routine hematology practice

Contact Info

Product

Resources

About